ZPC-21

N/A

Report date: 2026/03/28 20:00:32

Base Information

Drug NameZPC-21

Drug Alias NameIM-1021ZPC-21

ClassificationBiologics > Protein drugs > Immunoglobulin > Antibody > Antibody conjugate > Antibody drug conjugate (ADC)Biologics > Protein drugs > Immunoglobulin > Antibody > Antibody conjugate > Antibody drug conjugate (ADC) > Payload > HC74 payload

Mechanisms of ActionAnti-Inactive tyrosine-protein kinase transmembrane receptor ROR1DNA topoisomerase I inhibitors

TargetsInactive tyrosine-protein kinase transmembrane receptor ROR1DNA topoisomerase I

Therapy Area/IndicationsSolid tumoursHematologic NeoplasmsNeoplasms

Global Approved IndicationsN/A

Approved Indications in ChinaN/A

Original Approved Country/TerritoryN/A

Original Approved DateN/A

Country/TerritoryUnited StatesSpain

CombinationsNo

Global Highest StatusPhase 1 Clinical

Highest Status in ChinaN/A

Originator CompaniesZentalis Pharmaceuticals Inc

China Registration ClassN/A

Develop Information

Active CompaniesImmunome Inc

Inactive CompaniesN/A

Active IndicationsSolid tumoursHematologic Neoplasms

Inactive IndicationsNeoplasms

Other Information

ATC CodeN/A